Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2022 Mar 10

PMID 35264932

Authors

Mengya Wang

Huayuan Liu

Zegang Ma

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can exert an anti-movement disorder effect. Therefore, the development of drugs that modulate the endocannabinoid system may be a novel strategy for the treatment of PD. However, eCB regulation is complex, with diverse cannabinoid receptor functions and the presence of dopaminergic, glutamatergic, and γ-aminobutyric signals interacting with cannabinoid signaling in the basal ganglia region. Therefore, the study of eCB is challenging. Here, we have described the function of the cannabinoid system in the basal ganglia and its association with PD in three parts (eCBs, cannabinoid receptors, and factors regulating the cannabinoid metabolism) and summarized the mechanisms of action related to the cannabinoid analogs currently aimed at treating PD. The shortcomings identified from previous studies and the directions that should be explored in the future will provide insights into new approaches and ideas for the future development of cannabinoid-based drugs and the treatment of PD.

Citing Articles

Pharmacotherapy for the core symptoms of autism spectrum disorder.

Tan P, Shen X, Zeng L, Weng X, Geng H J Zhejiang Univ Sci B. 2024; 25(11):956-971.

PMID: 39626879 PMC: 11634452. DOI: 10.1631/jzus.B2300864.

Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease.

Khaspekov L, Illarioshkin S Int J Mol Sci. 2024; 25(15).

PMID: 39126088 PMC: 11312457. DOI: 10.3390/ijms25158520.

Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson's Disease.

Urmeneta-Ortiz M, Tejeda-Martinez A, Gonzalez-Reynoso O, Flores-Soto M Parkinsons Dis. 2024; 2024:5519396.

PMID: 39104613 PMC: 11300097. DOI: 10.1155/2024/5519396.

A single-center real-life study on the use of medical cannabis in patients with dystonia.

Anis S, Faust-Socher A, Sverdlov D, Lassman S, Hezi N, Anis O Front Neurol. 2023; 14:1218300.

PMID: 37456642 PMC: 10339647. DOI: 10.3389/fneur.2023.1218300.

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson's Disease.

Angelopoulou E, Bougea A, Paudel Y, Georgakopoulou V, Papageorgiou S, Piperi C Medicina (Kaunas). 2023; 59(6).

PMID: 37374342 PMC: 10301401. DOI: 10.3390/medicina59061138.

References

Lerner T, Kreitzer A . RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron. 2012; 73(2):347-59. PMC: 3269032. DOI: 10.1016/j.neuron.2011.11.015. View

Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams R, Moore J, Arevalo-Martin A . CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci. 2007; 25(3):629-34. DOI: 10.1111/j.1460-9568.2007.05322.x. View

Blazquez C, Chiarlone A, Bellocchio L, Resel E, Pruunsild P, Garcia-Rincon D . The CB₁ cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 2015; 22(10):1618-29. PMC: 4563779. DOI: 10.1038/cdd.2015.11. View

Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M . Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014; 17(8):1022-30. DOI: 10.1038/nn.3743. View

Castillo P, Younts T, Chavez A, Hashimotodani Y . Endocannabinoid signaling and synaptic function. Neuron. 2012; 76(1):70-81. PMC: 3517813. DOI: 10.1016/j.neuron.2012.09.020. View

Muccioli G . Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today. 2010; 15(11-12):474-83. DOI: 10.1016/j.drudis.2010.03.007. View

Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B, Jenner P, Ramos J . Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2002; 14(11):1827-32. DOI: 10.1046/j.0953-816x.2001.01812.x. View

Bravo-Ferrer I, Cuartero M, Zarruk J, Pradillo J, Hurtado O, Romera V . Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke. Stroke. 2016; 48(1):204-212. DOI: 10.1161/STROKEAHA.116.014793. View

Laun A, Shrader S, Brown K, Song Z . GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 2018; 40(3):300-308. PMC: 6460361. DOI: 10.1038/s41401-018-0031-9. View

10.

Haber S, Calzavara R . The cortico-basal ganglia integrative network: the role of the thalamus. Brain Res Bull. 2008; 78(2-3):69-74. PMC: 4459637. DOI: 10.1016/j.brainresbull.2008.09.013. View

11.

Fox S, Henry B, Hill M, Crossman A, Brotchie J . Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002; 17(6):1180-7. DOI: 10.1002/mds.10289. View

12.

Marxreiter F, Regensburger M, Winkler J . Adult neurogenesis in Parkinson's disease. Cell Mol Life Sci. 2012; 70(3):459-73. PMC: 11113680. DOI: 10.1007/s00018-012-1062-x. View

13.

Amenta P, Jallo J, Tuma R, Elliott M . A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res. 2012; 90(12):2293-305. DOI: 10.1002/jnr.23114. View

14.

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

15.

Mezey E, Toth Z, Cortright D, Arzubi M, Krause J, Elde R . Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. 2000; 97(7):3655-60. PMC: 16295. DOI: 10.1073/pnas.97.7.3655. View

16.

Sawzdargo M, Nguyen T, Lee D, Lynch K, Cheng R, Heng H . Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999; 64(2):193-8. DOI: 10.1016/s0169-328x(98)00277-0. View

17.

Gyorfi O, Nagy H, Bokor M, Moustafa A, Rosenzweig I, Kelemen O . Reduced CA2-CA3 Hippocampal Subfield Volume Is Related to Depression and Normalized by l-DOPA in Newly Diagnosed Parkinson's Disease. Front Neurol. 2017; 8:84. PMC: 5355434. DOI: 10.3389/fneur.2017.00084. View

18.

Tanimura A, Uchigashima M, Yamazaki M, Uesaka N, Mikuni T, Abe M . Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. Proc Natl Acad Sci U S A. 2012; 109(30):12195-200. PMC: 3409771. DOI: 10.1073/pnas.1204404109. View

19.

Jordan C, Xi Z . Progress in brain cannabinoid CB receptor research: From genes to behavior. Neurosci Biobehav Rev. 2019; 98:208-220. PMC: 6401261. DOI: 10.1016/j.neubiorev.2018.12.026. View

20.

Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J, Shriver L . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007; 13(4):492-7. DOI: 10.1038/nm1561. View